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RegulationThe nucleation-growth model has been used extensively for characterizing in vitro amyloid ﬁbril
formation kinetics and for simulating the relationship between amyloid and disease. In the majority
of studies amyloid has been considered as the dominant, or sole, aggregation end product, with the
presence of other competing non-amyloid aggregation processes, for example amorphous aggregate
formation, being largely ignored. Here, we examine possible regulatory effects that off-pathway pro-
cesses might exert on the rate and extent of amyloid formation – in particular their potential for
providing false positives and negatives in the evaluation of anti-amyloidogenic agents. Furthermore,
we investigate how such competing reactions might inﬂuence the standard interpretation of
amyloid aggregation as a two-state system. We conclude by discussing our ﬁndings in terms of
the general concepts of supersaturation and system metastability – providing some mechanistic
insight as to how these empirical phenomena may manifest themselves in the amyloid arena.
Crown Copyright  2015 Published by Elsevier B.V. on behalf of Federation of European Biochemical
society. All rights reserved.1. Introduction
Over the last ﬁfty-years the product of a particular class of
protein aggregation reaction, known as amyloid, has come to the
fore as the potential instigator of a disparate range of diseases
collectively termed amyloidosis [1–3]. The current mechanistic
paradigm of amyloid formation describes it as comporting to a
nucleated-growth (NG) model akin to that used to describe crystal
formation [3–8]. The NG model may be simply interpreted as a
sequential-stepwise-process ﬁrst involving a relatively slow/unfa-
vorable primary nucleation event (capable of creating the basic
amyloid structural unit) which is then followed by a rapid/favor-
able growth stage in which the basic amyloid unit can undergo
growth by monomer addition/monomer loss, ﬁbre joining/ﬁbre
breakage or a mixture of the two (Eq. (1)) [3,9,10]. Changes in
the individual parameters expressed in Eq. (1) have predictable
consequences (described in Table 1) on the amyloid kinetic proﬁle.It is this regular correspondence that allows both empirical
assignment and mechanistic causation to be inferred from the
differential kinetic behavior exhibited by amyloid when grown
under two types of conditions [3,4,6,11].
Nucleation nðMÞ ¢knþ
kn
N ð1aÞ
Growth N þM ¢
kgþ
kg
Anþ1fþMg ¢
kgþ
kg
   ð1bÞ
Breakage Ap!kb Ai þ Aj ð1cÞ
Joining As þ At !
kj
Aq ð1dÞ
The characteristic empirical behavior encoded in Eq. (1) and
described in Table 1 is predicated upon the experimental system
conforming to a single class of aggregation pathway. For the in vitro
case, experimental conditions can be achieved which satisfy the
requirement of yielding a single structural class/strain of amyloid
ﬁber [12,13]. However under ‘non-optimized’ in vitro conditions
[14–18], or under non-controllable in vivo situations [19,20], there
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a single pathway requirement [3,11]. In such cases, aggregation
may occur along multiple pathways with a variety of protein
aggregation products, both amyloid and other types, being pro-
duced [13–15]. As a result the standard consequences arising from
a nucleated growth-type mechanism for amyloid (outlined in
Table 1), previously taken to be axiomatic, may not be applicable.
In the current work, we have examined likely possible effects of
the existence of competing aggregation reactions on the time
course and equilibrium extent of amyloid formation. Two modes
of protein aggregation, amyloid formation and non-speciﬁc
agglomeration,1 were considered to be in direct competition for a
common pool of monomer (Fig. 1). Amyloid formation was treated
as a one-dimensional nucleated growth process [3,8,22–24]. In the
mathematical realization of this model, all chemical species were
simulated using an explicit approach [23] featuring ﬁbril nucleation,
ﬁber growth by monomer extension and internal and end-fragmen-
tation of polymer (Fig. 1). The size-speciﬁc forward and backwards
rate constants governing the amyloid formation reaction2 are
respectively denoted by kf_i,1AF and kb_i,jAF. The non-speciﬁc aggrega-
tion process was considered as a series of diffusion limited reactions3
for which the aggregate can reversibly grow and shrink through
monomer addition and monomer loss (Fig. 1). As for the amyloid
ﬁbers, the non-speciﬁc agglomeration process was also modeled
explicitly, with the rate constants for each step assigned on the basis
of a diffusion collision model which considered the ith aggregate
(i.e. aggregate species composed of i monomers) to have geometric
properties deﬁned by the following relationships for volume, V and
radius, R; Vi = iV1; Ri = [3iV1/(4p)]1/3. For the interaction of one sphe-
rical species with another, the diffusion collision scheme predicts a
functional dependence of the growth rate on monomer size as per
Eq. (2a) (justiﬁcation provided in Appendix 1). Assuming that mono-
mer contained within non-speciﬁc aggregate can dissociate most
easily from the aggregate’s surface we have set the size speciﬁc dis-
sociation rate constant proportional to surface area (Eq. (2b)).
kNSf i;1 ¼ kNSf 1;1  ð2þ i1=3 þ i1=3Þ=4 ð2aÞ
kNSb i;1 ¼ kNSb 1;1  i2=3 ð2bÞ
The values of forward and backward rate constants for the
amorphous aggregation reaction (that form the basis for the scal-
ing in Eq. (2)) were chosen to explore the often invoked assump-
tion – that amyloid represents the lowest energy structural state
available to the protein [27,28]. Due to their presumed diffusion
limited nature (Eq. (2)) we set the values of kf_1,1NS and kb_1,1NS in rela-
tion to kf_1,1AF and kb_1,1AF to affect behavior in which non-speciﬁc
aggregate was formed faster but was ultimately less thermody-
namically stable than the competing amyloid. Based on the rele-
vant experimental procedures [29–32] we transformed the
simulated time courses into an equivalent pseudo-experimental
signal based on the following two experimental observations.
Observation 1: All species heavier than the monomer can be differ-
entially sedimented or ﬁltered and therefore both non-speciﬁc
aggregate and amyloid are retained in the pellet/ﬁlter [29,31].
Observation 2: Amyloid exhibits a positive Thioﬂavin T binding
response whereas non-speciﬁc aggregate exhibits no Thioﬂavin T
binding ability [30,32].1 We use the terms non-speciﬁc agglomeration, non-speciﬁc aggregation and
amorphous aggregation interchangeably throughout this paper.
2 Although a method has been developed for assigning size dependent values for
these rate constants for a linear growth model [24,25] here we have simpliﬁed the
process by assigning a set of ﬁxed values for the respective nucleation, growth and
breakage steps.
3 The diffusion limited regime has historically been termed as perikinetic aggre-
gation [26].2. Results
Six different cases of an aggregation reaction were simulated in
which amyloid growth competed against amorphous aggregation
for monomer (Fig. 2). Fig. 2A represents a species plot description
of the temporal evolution of amyloid (red lines) and non-speciﬁc
aggregate (black lines) components. The fundamental rate con-
stants deﬁning the non-speciﬁc agglomeration component of the
aggregation reaction were varied through the six simulations to
transition from relatively fast to relatively slow aggregation. In this
study, fast and slow designations are made relative to the rate of
amyloid formation (see ﬁgure legend). In the absence of competi-
tion by amyloid, all sets of non-speciﬁc agglomeration rate con-
stants would incorporate practically all monomer into the non-
speciﬁc aggregate form.
From the information provided in the species plot progress
curves, we sought to develop a range of realistic experimental
measures of the aggregation process. Two closely related proce-
dures for monitoring the progress of an aggregation reaction
involve either the centrifugal or ﬁltration-based separation of all
species larger than a predetermined size limit – commonly chosen
to be that of the monomer4 [30,31]. Fig. 2B describes the total
amount of protein that would be recorded by such a pelleting/ﬁltra-
tion assay for the six simulation cases described in Fig. 2A (thick to
thin blue lines representing transition from fast to slow non-speciﬁc
aggregation with green line representing zero non-speciﬁc aggrega-
tion). Note that the classical sigmoidal pattern typically associated
with amyloid formation is restored. Another frequently-used proce-
dure for recording the kinetics of amyloid formation involves the use
of amyloid speciﬁc dyes such as Thioﬂavin T [29,32] and Congo Red
[33]. These dyes show a concerted change in spectral properties
upon binding to amyloid and can thus provide a near continuous
measure of its formation. Fig. 2C describes the simulated ﬂuores-
cence trace that would be recorded for a Thioﬂavin T dye-binding
analysis of amyloid formation over the six simulation cases (thick
to thin orange lines representing fast to slow transition in the
agglomeration reaction with green line describing a zero rate). Tech-
niques based on the measurement of light scattered from puriﬁed
aggregate fractions (such as DLS and SEC-MALLS [34,35]) can provide
some information on the size distribution and structure of the aggre-
gate – such as average molar mass. Fig. 2D shows the time depen-
dence of the number average molecular weight of two types of
aggregate, amyloid (red) and non-speciﬁc agglomerate (black) over
the six simulation cases explored (thick to thin lines describing the
transition from fast to slow agglomeration rate).
3. Discussion
Perhaps the most remarkable feature of the current study is the
degree to which the inclusion of a competing non-speciﬁc pathway
can radically change the shape and characteristic kinetics of the
amyloid progress curve (Fig. 2C). This point is notable for two dif-
ferent reasons relating to (i) in vitro screening of potential anti-
amyloid agents/conditions, and (ii) modelling of the role of amy-
loid in amyloidosis diseases.
With regard to point (i) in vitro screening of anti-amyloid agents;
oftentimes, the underlying goal behind an amyloid formation assay
is the evaluation of the ability of a drug, ligand, or set of buffer
conditions to limit amyloid growth [36–44]. As indicated by the
current simulations, there is signiﬁcant potential for any observed
anti-amyloid effect to be due to stimulation/retardation of a
competing pathway, which may/may not be operative under the
pertinent in vivo conditions. Further to this point, when comparing4 A very similar result is produced by ﬁlter binding/ﬁltration assay [31].
Table 1
Consequences for amyloid kinetics of parameter changes within the nucleation-growth model.
Parametera Consequencesb
Monomer concentration (M) (1) An increase in monomer concentration leads to an increase in the rate and extent of amyloid formation (weight
concentration) [3,7,8,11,21–23,28]
(2) An increase in monomer concentration can either increase or reduce the initial amyloid size distribution depend-
ing upon its relative effect on nucleation and growth rates [21,22]
Nucleation rate (kn+, kn) (1) For situations limited to the NGmodel i.e. intrinsic rate of nucleus formation intrinsic rate of amyloid formation,
or alternatively, equilibrium extent of nucleus formation  extent of amyloid, an increase in nucleation rate will
increase the rate of amyloid formation (weight concentration). Beyond this regime the rate and extent of amyloid
formation can decrease in response to a large amount of nucleus production [21,22]
(2) An increase in the nucleation rate will lead to a general shortening of the amyloid size distribution – note this con-
clusion can be affected by other parameters such as the ﬁber joining rate and the ﬁber fragmentation rate [21–23]
Nucleation size (n) In the classical Oosawa–Asakura model of helical polymer formation [7], an increase in the molecularityc of the nucleation
reaction will lower the concentration of the critical nucleus. This will concomitantly
(1) Slow the rate of amyloid formation (weight concentration) [21,22]
(2) Increase the size distribution of amyloid (average molecular weight) [21,22]
Growth rate by monomer addition (kg+) Increasing the rate of monomer addition to amyloid ﬁbrils will tend to
(1) Increase the rate of amyloid formation (weight concentration) [8,21]
(2) Increase the size distribution of amyloid (average molecular weight)
Dissociation rate by monomer loss (kg) Slower rates of monomer dissociation from amyloid ﬁbrils will tend to
(1) Increase the rate of amyloid formation (weight concentration)
(2) Increase the size distribution of amyloid (average molecular weight)
Fiber breakage rate (kb) Fiber breakage rates have been shown to display different behaviors
(1) At low breakage rates (relative to total amyloid growth rate) increases in breakage rate will lead to a net increase
in amyloid growth rate. At high ﬁber breakage rates (relative to the total amyloid growth rate) further increases in
ﬁber breakage rate lead to a dissolution of amyloid ﬁbers and a massive shortening of the ﬁber distribution
[8,10,21,23]
(2) Increases in ﬁber breakage rate always tend toward a shortening of the amyloid size distribution [8,10,21,23]
Fiber joining rate (kj) The effect of variation in ﬁber joining rate on both the rate of amyloid formation and the amyloid ﬁber distribution
properties has been less well studied [9,10]. Intuitively, we may propose that increasing the ﬁber joining rate will,
(1) Decrease the total rate of amyloid formation
(2) Increase the amyloid size distribution
a Parameters refer to rate constants governing the elementary steps of the nucleated growth scheme shown (Eq. (1)).
b Here we draw a distinction between two types of amyloid growth. The ﬁrst refers to the total mass of monomer incorporated into amyloid i.e. weight concentration. The
second refers to the general size of the amyloid size distribution i.e. average molecular weight [8,22,23].
c By molecularity we mean the number of molecules involved in the reaction.
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ferent model systems, the lack of a common set of competing
aggregation pathways between the systems may complicate the
interpretation of the screening results if the drug/conditions differ-
entially stimulate the competing pathways particular to each sys-
tem. One such example of a potentially complicated drug action
comes from the apparent inhibition of various amyloid species
by the ﬂavonoid ()-epigallocatechin 3-gallate (EGCG) [45–47].
Dispute over the exact nature of the anti-amyloid mechanism of
EGCG stems from its contested dual potential to either stabilize
competing micelle-products [46] or destabilize the amyloid direct-
ly [45,47]. In the light of the ﬁndings of the present study, the
potential for the absence of a direct anti-amyloidogenic activity
of this inhibitor is extant. Another example of the potential compli-
cating effects of a competing pathway lies in the work of Chiti and
coworkers who sought to deﬁne the factors affecting the absolute
reaction rates of protein aggregation [48–51]. The mainstay of the-
se early studies was muscle acyl phosphatase – a protein shown by
the same authors to form both amyloid and amorphous aggrega-
tion products [51]. Their adopted algorithmic approach involved
parameterizing the effects of variations in temperature, ionic
strength, pH and protein intrinsic factors in terms of aggregation
kinetics recorded by pelleting assay and Thioﬂavin T dye binding
assays. The ﬁndings presented in the current paper suggest that
care must be placed in the choice of basis set data for formulation
of any such amyloid propensity scales [49,50] due to the many
orders of magnitude differences that may potentially be brought
about by the presence of a competing pathway (Fig. 2).
With regard topoint (ii)modelling of the role of amyloid in the amy-
loidosis diseases; the main aim in using kinetic-rate-model simula-tions in amyloidosis research lies in the exploration of possible
linkages between amyloid formation and the different stages of dis-
ease onset/symptomatic display [3,23]. Due to its fundamental con-
nection to the underlying chemical physics, the NG paradigm has
been the mainstay of such modelling efforts in vitro [3,5,6,11,28].
However in transitioning from the test-tube to the patient, many
have assumed that amyloid formation in the body may be describ-
able in terms of the framework of the NGmodel, and have used this
model as a chemical scaffold uponwhich to build theories of disease
progression [3,23,52,53]. In such a conceptualization the chemical
environment in which the protein is placed is implicitly considered
in the sense that it may act to alter the statistical likelihood of an
individual step in the pathway but is not fundamentally required
for the step tooccur– i.e. thehumanbody is treatedas a reactionves-
sel deﬁning a unique set of rate constants for Eq. (1). However the
presence of a competing pathway will upset this deterministic con-
ceptualization of aggregate growth. In the current study the pres-
ence of a competing pathway has been shown to be operationally
equivalent to a complex time dependent function of the availability
of free protein i.e. CM(t) = f(t; X1, X2,..). Such a time-dependent func-
tionalization of the free monomer concentration in terms a set of
parameters [X1, X2,..] has not been widely (if at all) discussed prior
to this point. However consideration of such a functionalization of
CMmay prove particularly insightful to understanding the causation
and timing of amyloidosis disease onset. For example an increased
production of protein monomer, as for leukemia related overpro-
duction of antibody light chain in AL amyloidosis, may be sufﬁcient
to causediseasephenotype/symptomatic display [54]. As previously
noted such a disease switch point may take the form of a change in
free monomer concentration, a change in total amyloid loading or a
Fig. 1. Top – schematic mechanism reﬂecting competition for monomer (small blue
spheres) between amorphous aggregation (black spheres) and amyloid formation
(red cubes). Bottom – four distinct types of elementary process are considered in the
competitive aggregation mechanism. (A) Nucleation: describes the formation of a
key structural or energetic intermediate that represents the bottle neck for further
aggregate growth. Kinetics are respectively speciﬁed by a series of bimolecular
reactions involving monomer addition to the growing pre-nucleus with second
order forward nucleation rate constants, kf_i<n,1AF (amyloid) and kf_i<n,1NS (non-speciﬁc
aggregation) having units of M1 s1. In the current case, nucleus size, n, is
arbitrarily modeled as a dimer for both modes of aggregation (i.e. n = 2). (B) Growth:
Growth of both amyloid and non-speciﬁc aggregate is considered to occur via
monomer addition with respective second-order forward rate constants written as
kf_iP1,1
AF (amyloid) and kf_iP1,1NS (with units of M1 s1). The growth stage for amyloid
formation is characterized by kf_i>n,1AF kf_i<n,1AF while the growth stage for non-
speciﬁc aggregation is deﬁned by kf_i>n,1NS = kf_i<n,1NS (i.e. no distinction between
nucleation and growth stages). (C) Breakage via monomer release: Both non-speciﬁc
aggregate and amyloid are considered to be able to decrease in size through release
of monomer, which subsequently reclaims its structural state operative under the
particular solution conditions (blue sphere). Breakage resulting in monomer release
for each type of aggregate is deﬁned by ﬁrst order rate constants kb_i,1AF and kb_i,1NS
having units of s1. In this paper both non-speciﬁc and amyloid monomer release
rates were assigned equal to the common value kb_1,1. (D) Breakage resulting in
release of two smaller aggregate species: This mode of breakage, describing the
division of an aggregate of size i + j into two separate aggregates of size i and j, was
deﬁned by a set of breakage rate constants kb_i,jAF and kb_i,jNS for the amyloid and
non-speciﬁc aggregation cases, respectively. However only amyloid was considered
as being able to undergo appreciable internal fragmentation i.e. kb_i,jAF > 0. All
internal modes of breakage were considered equal for the amyloid case such that
kb_i,j
AF = kb_i,1AF (for all i, j). As the non-speciﬁc aggregate was modeled as a sphere,
internal fragmentation was considered much less likely than monomer release i.e.
kb_i,j
NS  0.
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tribution (Fig. 2) [3,23].
A ﬁnal point worthy of discussion is the general similarities that
can be drawn between the kinetic behavior observed in the current
simulations and the physical phenomenon of supersaturation
[55,56]. Supersaturation describes a non-equilibrium state of a sys-
tem for which its full transition to its new equilibrium state has
been kinetically limited thereby leading to a long-lived metastable
intermediate. One pertinent example of supersaturation is the abil-
ity to increase a liquid’s dissolved gas content above its known
solubility limit, when the liquid lacks competent nucleation cen-
ters for bubble formation such as might be produced by containers
possessing pitted walls capable of accommodating signiﬁcant
amounts of dissolved gas [57,58]. At a purely empirical level the
simulations in the current paper describe a slow kinetic transition
from initial monomer to ﬁnal amyloid states (Fig. 2) which proceed
via formation of a non-speciﬁc aggregate intermediate (NS-AGG)
(Eq. (3)).
MONOMER! fNS-AGGg ! AMYLOID ð3Þ
In this context we note that the kinetically limited transition of
protein to the amyloid state observed in the current studies can, by
analogy, be interpreted as a supersaturation process [14,57,58].5 In
general the relative coarseness of the experimental measurement
techniques used to record the formation of amyloid oftentimes
impose an artiﬁcial ‘two-phase’ conceptualization upon the system
i.e. the measurement signal either designates the protein as soluble
monomer or aggregate (Eq. (4a) – Fig. 2B) or alternatively as amyloid
ﬁber or non-amyloid ﬁber (Eq. (4b) – Fig. 2C).
MONOMER! AGGREGATE ð4aÞ
NON-AMYLOID! AMYLOID ð4bÞ
Although higher-order structural and analytical methods are
capable of providing a richer picture of the heterogeneous nature
of the aggregate distribution (Fig. 2D), necessarily over-simplistic
strategies, employed in the data-reduction associated with these
techniques, also lead to a similar two-phase interpretation being
imposed upon the system post-experiment. So, whether due to
limitations of the experimental methodology or of the methods
used for data reduction/analysis, the operative transition for study
is a type of two-state transition as represented by Eq. (4). However,
the complex multi-phase kinetics of amyloid production seen in
Fig. 2c does not easily comport to such a two-state system. In light
of the previous discussion of supersaturation, the non-speciﬁc
protein aggregate form presents itself as an obvious candidate
for the metastable species responsible for supersaturation-like
delayed production of the amyloid phase from the monomer
[14,44,46,55–58].
In conclusion, this study has highlighted some of the empirical
consequences of a protein aggregation mechanism possessing an
amorphous competing reaction pathway in addition to the amyloid
forming pathway. The real-life manifestations of such a com-
petitive growth scheme will undoubtedly be more complex than
the simple two-state system investigated here. We brieﬂy discuss
some of the higher order complexity that may be introduced by
multiple competing species in Appendix 2. However we believe
that the general physical principles which determine the system
behavior are captured within this study and therefore our results
may prove instructional to others working on the same, or closely
related, problems.5 In that its concentration dictates a phase shift which is slow to occur due to a
long-lived metastable intermediate.
Fig. 2. Simulation of the kinetics of amyloid versus non-speciﬁc aggregate growth in a situation whereby both modes of aggregation are competing for a common pool of
monomer: Amyloid formation was deﬁned throughout all kinetic simulations by a set of common rate constants (values listed below) which, in the absence of any competing
non-speciﬁc aggregation pathway, would return an identical kinetic proﬁle (green lines). The fundamental rate constants deﬁning the non-speciﬁc agglomeration component
of the aggregation reaction were varied from relatively fast to relatively slow aggregation carried out in six stages (values described below). (A) Time-dependent species plot:
the two types of competing aggregate from a single simulation are designated by lines of the same thickness/marking pattern with black referring to non-speciﬁc aggregate
and red describing amyloid formation. (B) Time-dependence of total aggregate: the total mass of aggregate, amyloid and non-speciﬁc agglomerate, as a function of time (as
would be recorded by ﬁlter binding or pelleting assays). (C) Time-dependence of Thioﬂavin T binding: simulated signal observed for Thioﬂavin T dye binding assay which
exhibits a positive ﬂuorescence signal when bound to aggregate species having a stacked intermolecular beta-sheet character i.e. amyloid. (D) Time-dependence of relative
molecular weight: Simulated case where aggregates are ﬁrst separated into their various types prior to determination of their relative molecular weight. Parameters for amyloid
rate constants and six stages of variation in non-speciﬁc rate constants (1) Amyloid: (kb_i,jAF = 5  104 s1, kf_1,1AF = 10 M1 s1, kf_i>1,1AF = 1000 M1 s1). (2) Non-Speciﬁc Aggregation:
Set 1: fastest agglomeration (thickest line, kb_1,1NS = 5  104 s1, kf_1,1NS = 500 M1 s1), Set 2: second fastest agglomeration (second thickest line, kb_1,1NS = 5  104 s1,
kf_1,1
NS = 250 M1 s1), Set 3: third fastest agglomeration (third thickest line: kb_1,1NS = 5  104 s1, kf_1,1NS = 100 M1 s1), agglomeration (fourth thickest line: kb_1,1NS = 5  104 s1,
kf_1,1
NS = 50 M1 s1), Set 5: slowest agglomeration (thin-dashed line: kb_1,1NS = 5  104 s1, kf_1,1NS = 10 M1 s1), Set 6: no agglomeration (green line: kb_1,1NS =
0 s1, kf_1,1NS = 0 M1 s1).
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received on an early draft of this manuscript.Appendix 1: Size dependence of non-speciﬁc aggregation
The diffusive collision rate between a spherical aggregate of i
monomers and a monomer (of radius Ri and R1 respectively), can
be calculated directly from Fick’s Laws [59,60]. The per unit area
ﬂux, j1, (molecules m2 s1) of monomers across some region of sur-
face surrounding an (initially) stationary aggregate i is given by,
j1 ¼ D1ð@C1=@rÞ ðA1Þ
Here D1 represents the monomer diffusion constant (m2 s1) and r
denotes the radial distance of the ﬂux boundary from the center of
the aggregate i. The total ﬂux of monomer, J1, (molecules s1)
through this surface region is,
J1 ¼ 4pr2D1ð@C1=@rÞ ðA2Þ
The total rate of collisions occurring at Ri1 (where Ri1 = Ri + R1)
can be obtained by separating and integrating the differential
(Eq. (A3)).
J1
1
r
 rRi1
r¼Ri1
¼ 4pD1½C1C1ðrRi1ÞC1ðr¼Ri1Þ ðA3Þ
Relaxing the requirement for aggregate i to be stationary and
expressing the total ﬂux in terms of the rate of molar collisions
between aggregate i and monomer yields Eq. (A4).
Ji1 ¼ 4pNAðDi þ D1ÞðRi þ R1ÞCiC1 ðA4Þ
Setting the diffusion constant for a spherical aggregate com-
posed of i monomers to be Di = kT/(6pgRi) where g is the dynamic
viscosity of the solvent yields a dependence of the associative col-
lision rate Ji1 on the size of aggregate i and monomer. The previous
development can be used to show that the forward rate of reaction
scales with both the ratio of diffusion constants and the ratio of the
collisional radius Ri1 = Ri + R1, yielding (Eq. (A5a)). With regards to
dissociation from the aggregate: for a spherical aggregate shape
the rate of monomer release from the aggregate is taken as a
ﬁrst-order process which scales with the ratio of surface area
(Eq. (A5b)).kNSf i;1
kNSf i;1
¼ ðRi þ R1Þ
2
4R1Ri
ðA5aÞ
kNSb i;1
kNSb i;1
¼ R
2
i
R21
ðA5bÞ
Expansion of Eqs. (A5a) and (A5b) along with their subsequent
combination with the non-speciﬁc volume relations described pri-
or to Eq. (2a) yield Eq. (2) in the main article. Interestingly, the the-
oretical development employed here, based solely on diffusive
encounter arguments, yields a one-third power dependence for
the aggregate rate constant on aggregate size rather than the
two-thirds power dependence predicted based on mean free path
and collisional cross section arguments derived for particle motion
in the gas phase. This difference represents an important distinc-
tion between these two regimes. A recent study by Stranks et al.
[61] develops an alternative result to the one presented here. By
application of scaling arguments, they derive an analytical
equation suggesting that the non-speciﬁc rate of incorporation of
monomer by spherical aggregates in the diffusion limited regime
should exhibit a two-thirds power dependence on particle size.
Interestingly much of the supporting experimental data on amor-
phous aggregation in the study by Stranks et al. [61] reﬂects an
experimental value closer to 1/3 than 2/3. Higher values of the
exponent may signify fractal like growth kinetics due to increasing
reactive surface area associated with an irregular non-speciﬁc
aggregate surface. Alternatively, the several assumptions required
in that work to develop a set of kinetic equations from the scaled
data may not be in the strongest form (i.e. assumption of irre-
versible aggregation, assumption of turbidity as a linear descriptor
of aggregate mass concentration).
Appendix 2: Potential complexities introduced by the existence
of multiple competing species
In the main paper we have modeled competition between amy-
loid and non-speciﬁc agglomerate as a contest for monomer
between just two structural forms of aggregate. In reality however
it is likely that multiple sub-types of each aggregate may exist. This
situation would yield an equation of the form (A6) for the total bal-
ance of populations (deﬁned in terms of the constituent concentra-
tions CAMYLOID and CNON-SPECIFIC). Eq. (A6) can be interpreted with
reference to a generalized nomenclature, (CAGG)qM which describes
an aggregate of degree of polymerization, q, of sub-type M, at a
number concentration C.
ðCAMYLOIDÞtotal ¼
XMAX
K¼1
max
i¼2
i  ðCAÞKi ðA6aÞ
ðCNON-SPECIFICÞtotal ¼
XMAX
D¼1
max
j¼2
j  ðCNSÞDj ðA6bÞ
The existence of a series of cascade like reactions in which
monomer is shuttled from one form to another before ﬁnally
reaching a low energy amyloid state would further complicate
the metastability issue addressed in the main paper. Interestingly
the introduction of a higher-order conceptualization of the aggre-
gate space would also greatly complicate the search for the
assumed toxic component of the aggregate distribution.
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